# **CERDELGA** (eliglustat)

#### **Pre - PA Allowance**

None

\_\_\_\_\_

# **Prior-Approval Requirements**

Age 18 years of age or older

**Diagnosis** 

Patient must have the following:

Type 1 Gaucher disease

#### AND ALL of the following:

- 1. Patient must be either CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.
- NO dual therapy with another medication for Type 1 Gaucher disease (see Appendix 1)

### **Prior - Approval Limits**

**Duration** 2 years

## Prior-Approval Renewal Requirements

**Age** 18 years of age or older

**Diagnosis** 

Patient must have the following:

Type 1 Gaucher disease

**AND** the following:

 NO dual therapy with another medication for Type 1 Gaucher disease (see Appendix 1)

# Prior-Approval Renewal Limits

Same as above



# **CERDELGA** (eliglustat)

### Appendix 1 - List of Hydrolytic Lysosomal Glucocerebroside Agents

Generic Name	Brand Name
eliglustat	Cerdelga
imiglucerase	Cerezyme
miglustat	Zavesca/Yargesa
taliglucerase alfa	Elelyso
velaglucerase alfa	VPRIV